List of Excipients in Branded Drug ADCIRCA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	CELLULOSE, MICROCRYSTALLINE
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	CROSCARMELLOSE SODIUM
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	FERRIC OXIDE RED
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	FERRIC OXIDE YELLOW
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	HYDROXYPROPYL CELLULOSE
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	HYPROMELLOSE
Aphena Pharma Solutions - Tennessee LLC	ADCIRCA	tadalafil	43353-070	LACTOSE MONOHYDRATE

# ADCIRCA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 21, 2026

ADCIRCA is the tadalafil 20 mg tablet marketed for pulmonary arterial hypertension (PAH). Its excipient platform is conventional, low-cost, and relatively easy to replicate: a lactose-based immediate-release tablet core with standard disintegrant, binder, lubricant, surfactant, and film-coating components. The commercial opportunity is therefore unlikely to come from proprietary excipient chemistry. It is more likely to come from supply reliability, differentiated patient-friendly formulations, regulatory execution, and distribution into PAH markets where generic access remains limited.

ADCIRCA has limited current protection from the tadalafil molecule itself. The central commercial barriers are clinical substitution, PAH-specialty distribution, payer access, manufacturing quality, and physician confidence rather than long-lived composition-of-matter exclusivity. There is no biosimilar pathway because tadalafil is a synthetic small molecule, not a biologic.

What is ADCIRCA and which excipients does the product use?

ADCIRCA contains tadalafil, a phosphodiesterase-5 inhibitor, at a 20 mg strength for once-daily oral treatment of PAH. The U.S. product is a film-coated, immediate-release tablet. The FDA-approved labeling identifies the following inactive ingredients in the tablet core and coating.[1]

Product element	ADCIRCA excipient	Functional role
Tablet core	Lactose monohydrate	Diluent and compressibility aid
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Hydroxypropyl cellulose	Binder
Tablet core	Sodium lauryl sulfate	Wetting agent and solubilization aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film-forming polymer
Film coating	Titanium dioxide	Opacifier and colorant
Film coating	Triacetin	Plasticizer
Film coating	Iron oxide yellow	Colorant
Film coating	FD&C Yellow No. 6 aluminum lake	Colorant
Film coating	Talc	Anti-tacking and coating aid

The formulation is consistent with a conventional immediate-release oral tablet. It does not depend on a modified-release polymer, lipid-based delivery system, enteric coating, nanocrystal technology, or device component.

What excipient strategy does ADCIRCA use?

ADCIRCA uses an established excipient architecture designed for robust manufacture rather than differentiation. Lactose provides bulk and tabletability. Croscarmellose sodium supports rapid tablet breakup, while hydroxypropyl cellulose provides granule or tablet-core cohesion. Sodium lauryl sulfate improves wetting of the hydrophobic active ingredient. Magnesium stearate supports high-speed tableting.

The film coat primarily provides identification, swallowability, protection from handling, and visual differentiation. The color system is commercially useful in a specialty market because PAH patients may take multiple chronic cardiovascular medicines, increasing the value of reliable product identification.

The strategy has four commercial implications:

1. Low technical entry barrier. Generic manufacturers can source equivalent excipients from multiple suppliers.
2. Limited formulation patent leverage. Standard excipients generally do not create meaningful exclusivity without a novel composition or manufacturing process.
3. Regulatory familiarity. The excipient set is widely used in approved oral medicines and is generally compatible with an abbreviated new drug application (ANDA) strategy.
4. Potential tolerability constraints. Lactose, colorants, sodium lauryl sulfate, and coating materials can create patient or market-segmentation issues, even when they do not create legal exclusivity.

What formulation opportunities exist for ADCIRCA or generic tadalafil?

The strongest opportunities involve differentiated tadalafil products rather than direct replication of the ADCIRCA tablet.

Lactose-free tadalafil tablets

A lactose-free formulation could target patients with lactose intolerance, excipient avoidance preferences, or institutional formularies that favor reduced excipient complexity. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, or directly compressible starch could replace lactose, subject to satisfactory dissolution, stability, and bioequivalence performance.

The opportunity is commercially credible but legally modest. A lactose-free tablet would usually be protected, if at all, by formulation or process claims that must survive obviousness and enablement challenges. It would not prevent ordinary generic substitution.

Colorant-reduced or colorant-free products

A colorant-free product could serve patients who avoid synthetic dyes or health systems seeking simpler excipient profiles. The tradeoff is loss of visual product differentiation. Packaging, debossing, blister configuration, or tablet shape would need to carry more of the identification burden.

Orally disintegrating tadalafil

An orally disintegrating tablet (ODT) could address patients with dysphagia, polypharmacy, or difficulty taking conventional tablets. The formulation challenge is meaningful because tadalafil is poorly water soluble. Taste masking, rapid dispersion, dose uniformity, and adequate drug release would require formulation development.

An ODT could support a new product position, but it would need a clinical and commercial rationale. PAH treatment is chronic and typically managed through specialty care. A differentiated dosage form would have greater value if it improves adherence or addresses a documented patient population rather than merely changing tablet presentation.

Tadalafil oral suspension

A liquid formulation could support patients unable to swallow tablets and potentially pediatric or feeding-tube use. Commercial value would depend on regulatory labeling, stability after opening, preservative selection, dosing accuracy, and reimbursement. A suspension could also create manufacturing and distribution burdens that do not exist for tablets.

Fixed-dose combination products

Tadalafil could theoretically be combined with other PAH therapies, but combination development faces pharmacokinetic, safety, and clinical-positioning issues. The main competitive products in PAH include endothelin receptor antagonists, prostacyclin-pathway therapies, and soluble guanylate cyclase stimulators. A fixed-dose tadalafil combination would require evidence that the product improves adherence or clinical use enough to justify development cost.

What patents protect ADCIRCA and when does tadalafil lose exclusivity?

ADCIRCA’s historical protection was based primarily on tadalafil-related patents and regulatory exclusivity, not on a distinctive excipient platform. The original tadalafil patent estate included U.S. patents associated with the tadalafil compound and pharmaceutical compositions. The principal U.S. exclusivity periods have expired or reached the end of their practical commercial life.[2][3]

Protection category	ADCIRCA relevance	Commercial status
Tadalafil composition patents	Protected the active pharmaceutical ingredient	Expired or no longer a durable barrier in the U.S.
Tadalafil composition and use patents	Supported tadalafil use in specified indications	Subject to expiration, litigation history, and claim scope
Orphan-drug exclusivity	Applied to tadalafil for PAH after ADCIRCA approval	Seven-year period from U.S. approval, ending in the late 2010s
Formulation patents	No widely recognized long-term ADCIRCA exclusivity based on the standard tablet excipient system	Limited strategic importance
Method-of-use patents	Could address PAH treatment or dosing claims	Dependent on listing, enforceability, and approved-label overlap
Pediatric exclusivity	Depends on FDA-issued pediatric study requirements	Product-specific and time-limited

The FDA approved ADCIRCA in May 2009 for PAH. Orphan-drug exclusivity generally lasts seven years from approval, placing the core ADCIRCA orphan period in 2016. Patent term adjustments, pediatric extensions, settlement agreements, and jurisdiction-specific rights can affect actual entry timing.[1][4]

What is the Orange Book status of ADCIRCA?

ADCIRCA is an FDA-approved small-molecule drug listed in the Orange Book framework. Generic applicants seeking approval must address listed patents through the ANDA certification process, including Paragraph III, Paragraph IV, or other applicable certifications.[2]

The practical importance of current Orange Book listings is lower than it was during the initial ADCIRCA launch period because the main tadalafil exclusivity barriers have aged. The key issues for a generic applicant are:

• Whether a patent remains listed for the relevant ADCIRCA strength and indication.
• Whether the proposed label overlaps a patented method of use.
• Whether the applicant can use a carve-out under section viii of the Hatch-Waxman Act.
• Whether a Paragraph IV notice triggers litigation and a potential 30-month stay.
• Whether the proposed product uses the same inactive ingredients or requires additional FDA justification.

The Orange Book does not create exclusivity for conventional excipients. An applicant generally cannot block a competing tadalafil product merely by using the same lactose, binder, disintegrant, lubricant, or film-coating system.

Which companies are challenging or competing with ADCIRCA?

ADCIRCA competes with generic tadalafil products and with other PAH therapies. The most important direct competitors are manufacturers that obtain FDA approval for tadalafil tablets labeled for PAH. Competition may arise from branded generics, authorized generics, specialty-pharmacy suppliers, and manufacturers using different tadalafil dosage forms.

The broader PAH market includes:

Therapy class	Examples	Competitive relationship to ADCIRCA
PDE-5 inhibitors	Tadalafil, sildenafil	Direct pharmacologic competition
Endothelin receptor antagonists	Ambrisentan, bosentan, macitentan	Alternative oral PAH therapy
Prostacyclin-pathway therapies	Epoprostenol, treprostinil, selexipag	Alternative or combination therapy
Soluble guanylate cyclase stimulators	Riociguat	Alternative mechanism; important label and safety considerations
Combination regimens	Tadalafil plus an endothelin receptor antagonist or other PAH drug	Common treatment strategy and a source of adherence challenges

ADCIRCA’s commercial position is shaped by PAH treatment guidelines, specialty pharmacy contracts, prior authorization, copay support, and hospital-to-outpatient transitions. Generic tadalafil may achieve rapid price erosion in open retail channels but face slower conversion where prescribers and specialty pharmacies prioritize continuity of supply.

What generic entry risks exist for ADCIRCA?

Generic entry risk is high at the active-ingredient level and moderate at the commercial level.

Regulatory risk

Tadalafil is a well-characterized small molecule. A conventional 20 mg tablet can generally pursue an ANDA pathway if the applicant demonstrates pharmaceutical equivalence and bioequivalence and satisfies labeling requirements.[5] The established excipients reduce development risk, although the applicant must address differences in inactive ingredients, colorants, product appearance, and manufacturing controls.

Manufacturing risk

The main technical risks are tadalafil’s low aqueous solubility, content uniformity, dissolution performance, and scale-up consistency. Sodium lauryl sulfate and particle-size control can materially affect wetting and dissolution. A generic manufacturer that changes the surfactant level, compression force, granulation method, or coating process may create dissolution or stability differences.

Commercial risk

PAH is a specialty indication with lower patient volume than erectile-dysfunction markets. A generic entrant must build relationships with specialty pharmacies, payers, pulmonary hypertension centers, and distributors. A low list price alone may not secure meaningful share.

Legal risk

A Paragraph IV challenge would create litigation exposure if any listed patent remained relevant. The commercial value of litigation depends on the remaining patent term, the scope of the asserted claims, the possibility of a 30-month stay, and whether the generic can launch with a label carve-out.[2]

How strong is the ADCIRCA patent estate?

The ADCIRCA patent estate is weak as a long-term barrier to ordinary generic tablet entry. The active ingredient is mature, the core formulation uses standard excipients, and the original orphan exclusivity period has ended.

Patent strength may still exist in narrower areas:

• New tadalafil dosage forms.
• Specific combinations with other PAH agents.
• Patient-selection methods.
• Dosing regimens with clearly defined clinical advantages.
• Manufacturing processes that improve purity, yield, particle size, or dissolution.
• Specialty formulations addressing dysphagia or enteral administration.

These claims would need to provide a measurable technical or clinical benefit. A patent covering a routine substitution of lactose with another common diluent would face a higher validity risk than a claim tied to unexpected dissolution, stability, bioavailability, or adherence results.

What licensing deals affect ADCIRCA?

ADCIRCA was developed and commercialized through a collaboration between Eli Lilly and United Therapeutics. United Therapeutics obtained rights related to tadalafil for PAH and commercialized ADCIRCA, while Eli Lilly retained its tadalafil franchise in other indications, including erectile dysfunction and benign prostatic hyperplasia.[6]

This split is commercially important. Tadalafil’s molecule supports multiple markets, but the PAH label, distribution model, and specialty-care relationships are distinct. Licensing or co-development opportunities involving ADCIRCA-related products would need to address indication rights, geographic territories, pharmacovigilance, specialty distribution, and potential channel conflict with Cialis or generic tadalafil.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have limited opportunity to create value through commodity supply alone. The stronger opportunities are:

1. Dual-source supply agreements. Lactose, hypromellose, croscarmellose sodium, magnesium stearate, and coating pigments can be qualified from multiple global suppliers to reduce interruption risk.
2. Direct-compression grades. Higher-functionality lactose, microcrystalline cellulose, or co-processed excipients can simplify manufacturing and reduce granulation steps.
3. Improved wetting systems. Surfactant or co-processed excipient platforms that improve tadalafil dissolution could support generic development.
4. Colorant alternatives. Dye-free or iron-oxide-based coating systems could support differentiated products.
5. Taste-masking systems. These are relevant to ODTs, chewable products, and liquid formulations.
6. Continuous manufacturing. Excipient systems optimized for content uniformity and dissolution during continuous processing could reduce scale-up risk.
7. Regulatory support. Suppliers with strong FDA Inactive Ingredient Database coverage, DMF support, and global compendial documentation have an advantage in ANDA and international submissions.[7]

The most defensible commercial proposition is a formulation package that improves dissolution or patient usability while preserving bioequivalence and manufacturing efficiency.

How does ADCIRCA compare with Cialis from an excipient and commercial perspective?

ADCIRCA and Cialis contain tadalafil, but they occupy different regulatory and commercial markets.

Attribute	ADCIRCA	Cialis
Active ingredient	Tadalafil	Tadalafil
Main indication	PAH	Erectile dysfunction and benign prostatic hyperplasia
Typical strength relevant to product	20 mg	2.5 mg, 5 mg, 10 mg, 20 mg
Distribution	Specialty and pulmonary hypertension channels	Retail, mail-order, telehealth, and specialty channels
Patient base	Smaller, chronic, medically complex	Larger and more consumer-driven
Excipient opportunity	Adherence, swallowing, specialty formulations	Broad dose-range and consumer formulation opportunities
Generic pressure	High for tadalafil tablets	High across multiple strengths and indications
Biosimilar risk	None	None

The same active ingredient does not make the commercial strategies interchangeable. ADCIRCA-related products must comply with PAH labeling and address specialty-market access. Cialis-related products have larger volume potential but more intense price and channel competition.

Key Takeaways

• ADCIRCA is a tadalafil 20 mg immediate-release film-coated tablet for PAH.
• Its excipient system is conventional and includes lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, sodium lauryl sulfate, magnesium stearate, and standard coating materials.
• The excipient platform creates little durable exclusivity.
• Tadalafil’s principal U.S. exclusivity barriers have expired or materially weakened.
• Generic entry risk is high, although specialty distribution and payer controls can slow commercial conversion.
• The best formulation opportunities are lactose-free tablets, dye-free products, ODTs, oral suspensions, and adherence-oriented combination products.
• Manufacturing and formulation patents are more defensible when tied to unexpected dissolution, stability, bioavailability, or production benefits.
• There is no biosimilar risk because ADCIRCA is a synthetic small-molecule drug.
• Excipient suppliers can create value through high-functionality grades, dissolution support, dual sourcing, and regulatory documentation.
• United Therapeutics’ PAH rights and Eli Lilly’s broader tadalafil franchise remain central to licensing and channel analysis.

FAQs

Can a generic ADCIRCA use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and labeling. The applicant must evaluate the regulatory impact of the change.

Is lactose-free tadalafil commercially attractive?

It can be attractive in institutional, specialty, and patient-preference segments. Its value depends on demonstrated tolerability or adherence benefits because lactose removal alone does not prevent ordinary generic substitution.

Does ADCIRCA have a proprietary coating technology?

The approved ADCIRCA labeling identifies conventional film-coating materials. The coating supports appearance and handling but does not indicate a standalone proprietary delivery platform.[1]

Can an ODT tadalafil product obtain new exclusivity?

Potentially, if the product is covered by valid patents or qualifies for applicable regulatory exclusivity. A new dosage form does not automatically receive exclusivity, and the applicant must establish the relevant clinical and bioequivalence requirements.

Are excipient suppliers exposed to ADCIRCA patent litigation?

Usually not directly. Litigation generally centers on the active ingredient, approved methods of use, formulation claims, or manufacturing processes. Suppliers may face commercial exposure through indemnity, supply continuity, or technical documentation obligations rather than as primary patent defendants.

References

1. U.S. Food and Drug Administration. (2009). ADCIRCA (tadalafil) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent and Trademark Office. (n.d.). Patent term and patent expiration information.
4. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs.
6. United Therapeutics Corporation. (2009). ADCIRCA tadalafil licensing and commercialization materials.
7. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.